Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enovis Corp (ENOV)

Enovis Corp (ENOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,367,583
  • Shares Outstanding, K 57,245
  • Annual Sales, $ 2,248 M
  • Annual Income, $ -1,184 M
  • EBIT $ 99 M
  • EBITDA $ 1,443 M
  • 60-Month Beta 1.46
  • Price/Sales 0.63
  • Price/Cash Flow 0.92
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 69.54% (-9.20%)
  • Historical Volatility 56.29%
  • IV Percentile 67%
  • IV Rank 42.02%
  • IV High 109.75% on 02/02/26
  • IV Low 40.40% on 03/26/25
  • Expected Move (DTE 8) 1.19 (4.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 162
  • Volume Avg (30-Day) 296
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 10,572
  • Open Int (30-Day) 9,394
  • Expected Range 23.65 to 26.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.82
  • Number of Estimates 2
  • High Estimate 0.83
  • Low Estimate 0.81
  • Prior Year 0.81
  • Growth Rate Est. (year over year) +1.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.59 +15.05%
on 02/18/26
26.41 -5.94%
on 02/27/26
+2.04 (+8.95%)
since 02/11/26
3-Month
21.00 +18.29%
on 01/29/26
29.89 -16.90%
on 01/12/26
-2.98 (-10.71%)
since 12/11/25
52-Week
21.00 +18.29%
on 01/29/26
40.69 -38.96%
on 03/25/25
-12.01 (-32.59%)
since 03/11/25

Most Recent Stories

More News
Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks

Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks

ENOV : 24.84 (+3.98%)
3 Unprofitable Stocks We Approach with Caution

3 Unprofitable Stocks We Approach with Caution

ENOV : 24.84 (+3.98%)
PACB : 1.3500 (-1.46%)
KRUS : 59.00 (-0.42%)
Why Enovis (ENOV) Stock Is Trading Up Today

Why Enovis (ENOV) Stock Is Trading Up Today

ENOV : 24.84 (+3.98%)
Enovis: Q4 Earnings Snapshot

Enovis: Q4 Earnings Snapshot

ENOV : 24.84 (+3.98%)
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Continued commercial momentum with full year 2025 sales growth of  7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and...

ENOV : 24.84 (+3.98%)
Enovis (NYSE:ENOV) Misses Q4 CY2025 Sales Expectations

Enovis (NYSE:ENOV) Misses Q4 CY2025 Sales Expectations

ENOV : 24.84 (+3.98%)
Enovis Announces Fourth Quarter and Full Year 2025 Results

Continued commercial momentum with full year 2025 sales growth of  7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and...

ENOV : 24.84 (+3.98%)
Enovis (ENOV) To Report Earnings Tomorrow: Here Is What To Expect

Enovis (ENOV) To Report Earnings Tomorrow: Here Is What To Expect

ENOV : 24.84 (+3.98%)
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know

Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know

ENOV : 24.84 (+3.98%)
IART : 9.61 (+0.63%)
BTSG : 41.33 (-0.02%)
CRL : 168.91 (+0.92%)
IQV : 171.58 (+0.38%)
1 Volatile Stock with Promising Prospects and 2 We Ignore

1 Volatile Stock with Promising Prospects and 2 We Ignore

ENOV : 24.84 (+3.98%)
COHR : 251.41 (-3.54%)
MCHP : 65.79 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Enovis Corporation is a medical technology company. Its range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. Enovis Corporation, formerly known as Colfax Corporation, is based in Wilmington, DE.

See More

Key Turning Points

3rd Resistance Point 26.79
2nd Resistance Point 25.84
1st Resistance Point 25.34
Last Price 24.84
1st Support Level 23.89
2nd Support Level 22.94
3rd Support Level 22.44

See More

52-Week High 40.69
Fibonacci 61.8% 33.17
Fibonacci 50% 30.85
Fibonacci 38.2% 28.52
Last Price 24.84
52-Week Low 21.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar